Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31412777 | 1.00 | ESR1 (1.00) | ESR1 | |
| SCHEMBL23186410 | 1.00 | ESR1 (1.00) | ESR1 | |
| SCHEMBL22213720 | 1.00 | ESR1 (1.00) | ESR1 | |
| SCHEMBL23783505 | 1.00 | ESR1 (1.00) | ESR1 | |
| SCHEMBL17839320 | 0.98 | ESR1 (1.00) | ESR1 | |
| SCHEMBL30123994 | 0.98 | ESR1 (1.00) | ESR1 | |
| SCHEMBL17839480 | 0.97 | ESR1 (0.98) | ESR1 | |
| SCHEMBL30124497 | 0.97 | ESR1 (0.98) | ESR1 | |
| SCHEMBL17839528 | 0.96 | ESR1 (1.00) | ESR1 | |
| SCHEMBL23722429 | 0.96 | ESR1 (1.00) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760623-B1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-03-18 | — | — | EP | claimed |
| EP-3760623-A1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | claimed |
| EP-3760623-B1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-03-18 | — | — | EP | disclosed |
| EP-4114391-B1 | COMPOSITIONS FOR USE IN A METHOD OF TREATING AN ESTROGEN RECEPTOR ASSOCIATED CANCER | OLEMA PHARMACEUTICALS INC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250114338-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12233052-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-11676731-B2 | Diagnostic and therapeutic methods for the treatment of breast cancer | GENENTECH, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11676731-B2 | Diagnostic and therapeutic methods for the treatment of breast cancer | GENENTECH, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2023091550-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | OLEMA PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091550-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | OLEMA PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230129598-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | OLEMA PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-9980947-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980947-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980947-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2017216280-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-21 | — | — | WO | disclosed |
| US-20170362228-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016097072-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233052-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | ESR2, GPER1, ESR1 | ESR1 3/4885 |
| US-20230129598-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | ESRRB, ESRRG, ESRRA | ESR1 6/4885 |
| US-20250114338-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | ESR1 3/4885 |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | ESR1 3/4885 |
| US-20170362228-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | ESR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.